You're invited to attend a complimentary breast cancer care webinar, “Cerianna™ (fluoroestradiol F 18) Injection PET/CT: Who and Why?” on Thursday, October 7, 2021 at 7:30 pm EST with Dr. Robert Bridwell.

During this webinar, he'll discuss unmet imaging needs in recurrent and metastatic breast cancer, estrogen receptor heterogeneity, the value of Cerianna PET/CT, and appropriate patients to consider for its use.

Registration is complimentary and open to all healthcare providers. Don't miss this informative event! Reserve your spot at www.oncologymeded.com

Learning Objectives

- Review the unmet imaging needs in recurrent and metastatic breast cancer
- Learn about estrogen receptor heterogeneity in metastatic breast cancer
- Recognize the value of Cerianna™ PET/CT and appropriate patients to consider for its use
- Review cases that demonstrate how determining full-body ER+ lesions status may impact patient care.

Robert Bridwell, MD
Chief Medical Officer
Appian 360

Important Safety Information for Cerianna™ (fluoroestradiol F 18) Injection

INDICATIONS AND USAGE

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

Limitations of Use

Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1%: were injection-site pain and dysgeusia.

To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp at +1.844.946.6392 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For full Prescribing Information click here.